Extract
Chronic breathlessness, which may be better described as persistent breathlessness to optimise applicability to different languages, is a frequent cause of disability in chronic obstructive pulmonary disease (COPD) [1]. In many people with advanced COPD, optimising treatment for the underlying causes of breathlessness and employing non-pharmacological approaches doesn't achieve symptom control [2]. Some people with persistent breathlessness may benefit from regular, low-dose, sustained-release (SR) morphine [3]. Importantly, changes in unidimensional breathlessness measures do not always reflect the patient's perspective of benefit [4].
Footnotes
This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.
Conflict of interest: DF has nothing to disclose.
Conflict of interest: MJ was a paid clinical consultant to Mayne Pharma.
Conflict of interest: DJ received research grants from the Netherlands Organisation for Health Research and Development (ZonMw), Stichting Astmabestrijding and NRS Award; provided paid lectures from Boehringer Ingelheim, Chiesi, Abbott; participated in the BETTER-B Trial Steering Committee, Scientific committee of the Wolfson Palliative Care Research Centre, Hull, UK, ERS Taskforce.
Conflict of interest: ME has nothing to disclose.
Conflict of interest: DC is on the Advisory Board member and paid consultant for Helsinn Pharmaceuticals; a paid consultant and receive payment for intellectual property with Mayne Pharma International Pty Ltd; a paid subcontractor to Nous Group Pty Ltd; a paid Board member for icare Dust Diseases Care NSW; unpaid Board member/Director for Chris O'Brien Lifehouse; Board member of IHMRI.
- Received August 1, 2022.
- Accepted October 17, 2022.
- Copyright ©The authors 2022. For reproduction rights and permissions contact permissions{at}ersnet.org